Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

Condition: WT1-Positive Tumors
Journal: Scientific reports
Treatment Used: WT2725 WT1-Derived Oligopeptide Vaccine
Number of Patients: 44
Published: November 17, 2021
View publication
Summary: This study tested the safety and efficacy of using WT2725 a WT1-derived oligopeptide vaccine to treat patients with WT1-positive tumors.

Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

Condition: Recurrent Ovarian Cancer
Journal: Journal for immunotherapy of cancer
Treatment Used: Autologous WT1-Sensitized T Cells
Number of Patients: 12
Published: August 26, 2021
View publication
Summary: The study researched the use of autologous WT1-sensitized T cells for treating recurrent ovarian cancer.

Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

Journal: International journal of molecular sciences
Published: July 24, 2021
View publication
Summary: Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Condition: Acute Myeloid Leukemia (AML)
Journal: Frontiers in immunology
Treatment Used: Combination Therapy with PD-1 Blockade after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Number of Patients: 1
Published: April 19, 2021
View publication
Summary: This article reviewed the case of a patient with acute myeloid leukemia (cancer of the blood and bone marrow; AML) treated with combination therapy with PD-1 blockade (class of drugs that block PD-1 protein) after allogeneic hematopoietic stem cell transplantation (transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood; ...

Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

Journal: Blood cells, molecules & diseases
Published: February 26, 2021
View publication
Summary: Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

Condition: Acute Myeloid Leukemia
Journal: Nature medicine
Treatment Used: T-Cell Receptor Gene Therapy after Hematopoietic Stem Cell Transplantation
Number of Patients: 12
Published: June 26, 2019
View publication
Summary: This study tested the safety and efficacy of using T-cell receptor gene therapy after a hematopoietic stem cell transplantation to treat patients with acute myeloid leukemia.

Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.

Condition: Head and Neck Cancer
Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Treatment Used: Willms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination combined with Conventional Chemotherapy
Number of Patients: 11
Published: April 30, 2019
View publication
Summary: This study tested the safety and efficacy of using a peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy to treat patients with head and neck cancer.

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Condition: Recurrent malignant glioma
Journal: Cancer immunology, immunotherapy : CII
Treatment Used: Cocktail vaccine of WT1 human leukocyte antigen class I and II peptides
Number of Patients: 14
Published: November 16, 2018
View publication
Summary: This study evaluated the safety and efficacy of a cocktail vaccine of WT1 human leukocyte antigen class I and II peptides for recurrent malignant glioma.

Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

Condition: Breast, ovarian, gastric cancer
Journal: Cancer immunology, immunotherapy : CII
Treatment Used: Dendritic cells vaccination with Wilms' tumor protein 1 (WT1)
Number of Patients: 10
Published: October 12, 2018
View publication
Summary: The study observed the effects of incorporating Wilms' tumor protein 1 (WT1) with Dendritic cell (DC)-based immunotherapies in advanced stages of breast, ovarian and gastric cancer. to Dendritic cell (DC)-based immunotherapies used as treatment for breast, ovarian and gastric cancer.

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Condition: Lower-risk Myelodysplastic Syndromes
Journal: Cancer science
Treatment Used: five-day regimen of azacitidine
Number of Patients: 51
Published: July 15, 2018
View publication
Summary: The study was conducted to examine the efficacy and safety of a 5-day regimen of azacitidine for lower-risk MDS

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Condition: Acute Myeloid Leukemia (AML)
Journal: Blood advances
Treatment Used: Multivalent WT1 Peptide Vaccine (Galinpepimut-S)
Number of Patients: 22
Published: February 02, 2018
View publication
Summary: This study investigated the multivalent WT1 peptide vaccine (galinpepimut- S) vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR1).
Showing 1-11 of 11